文献速递精神分裂症与精神病性障碍

认知行为治疗用于氯氮平抵抗性精神分裂症(FOCUS):评估者盲法随机对照试验

Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial.
PubMed 文献 · Lancet Psychiatry · 2018-07-11

该务实、平行组、评估者盲法随机对照试验在英国五个中心纳入487例氯氮平抵抗或无法耐受氯氮平的精神分裂症患者,比较CBT联合常规治疗与单用常规治疗。不良事件两组相似。

要点

  • 21个月随访时CBT对精神分裂症总症状无持久效应。
  • 治疗结束(9个月)时CBT组PANSS总分有统计学但非临床显著改善。
  • CBT联合常规治疗未增加不良事件,试验相关严重不良事件罕见。

核心结论

  • 21个月随访时CBT对氯氮平抵抗性精神分裂症的总症状无持久效应,但治疗结束时有统计学显著而非临床显著的改善。
  • 结果不支持常规对所有符合氯氮平抵抗性精神分裂症标准者提供CBT,但部分患者可考虑个体化尝试。

研究设计与样本

  • 务实、平行组、评估者盲法随机对照试验,在英国五个社区和住院精神卫生服务机构开展。
  • 纳入无法耐受氯氮平或症状对氯氮平无应答的精神分裂症患者,按1:1随机分配至CBT联合常规治疗或单用常规治疗,按中心分层。
  • 共随机分配487例(CBT组242例,常规治疗组245例),主要分析纳入CBT组209例和常规治疗组216例。
  • 主要结局为21个月时PANSS总分,治疗结束(9个月)时也评估PANSS总分。
  • 主要分析基于意向治疗,仅纳入有数据患者;试验前瞻性注册号ISRCTN99672552。

主要发现

  • CBT组242例中2例(1%)和常规治疗组245例中1例(<1%)发生试验相关严重不良事件。

临床怎么用

  • 不应常规对所有氯氮平抵抗性精神分裂症患者提供CBT。
  • 对部分患者可考虑个体化尝试CBT,需结合患者具体情况。
  • CBT联合常规治疗未显示增加不良事件风险。

局限性

  • 主要分析仅纳入有数据患者,非全部随机化患者。
  • 9个月时的PANSS改善虽统计学显著但未达临床显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although clozapine is the treatment of choice for treatment-refractory schizophrenia, 30-40% of patients have an insufficient response, and others are unable to tolerate it. Evidence for any augmentation strategies is scarce. We aimed to determine whether cognitive behavioural therapy (CBT) is an effective treatment for clozapine-resistant schizophrenia. METHODS: We did a pragmatic, parallel group, assessor-blinded, randomised controlled trial in community-based and inpatient mental health services in five sites in the UK. Patients with schizophrenia who were unable to tolerate clozapine, or whose symptoms did not respond to the drug, were randomly assigned 1:1 by use of randomised-permuted blocks of size four or six, stratified by centre, to either CBT plus treatment as usual or treatment as usual alone. Research assistants were masked to allocation to protect against rater bias and allegiance bias. The primary outcome was the Positive and Negative Syndrome Scale (PANSS) total score at 21 months, which provides a continuous measure of symptoms of schizophrenia; PANSS total was also assessed at the end of treatment (9 months). The primary analysis was by randomised treatment based on intention to treat, for all patients for whom data were available. This study was prospectively registered, number ISRCTN99672552. The trial is closed to accrual. FINDINGS: From Jan 1, 2013, to May 31, 2015, we randomly assigned 487 participants to either CBT and treatment as usual (n=242) or treatment as usual alone (n=245). Analysis included 209 in the CBT group and 216 in the treatment as usual group. No difference occurred in the primary outcome (PANSS total at 21 months, mean difference -0·89, 95% CI -3·32 to 1·55; p=0·48), although the CBT group improved at the end of treatment (PANSS total at 9 months, mean difference -2·40, -4·79 to -0·02; p=0·049). During the trial, 107 (44%) of 242 participants in the CBT arm and 104 (42%) of 245 in the treatment as usual arm had at least one adverse event (odds ratio 1·09, 95% CI 0·81 to 1·46; p=0·58). Only two (1%) of 242 participants in the CBT arm and one (<1%) of 245 in the treatment as usual arm had a trial-related serious adverse event. INTERPRETATION: At 21-month follow-up, CBT did not have a lasting effect on total symptoms of schizophrenia compared with treatment as usual; however, CBT produced statistically, though not clinically, significant improvements on total symptoms by the end of treatment. There was no indication that the addition of CBT to treatment as usual caused adverse effects. The results of this trial do not support a recommendation to routinely offer CBT to all people who meet criteria for clozapine-resistant schizophrenia; however, a pragmatic individual trial might be indicated for some. FUNDING: National Institute for Health Research Technology Assessment programme.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Morrison AP, Pyle M, Gumley A, et al. Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. Lancet Psychiatry. 2018. PMID: 30001930. doi:10.1016/S2215-0366(18)30184-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。